Rock Springs Capital Management LP Corvus Pharmaceuticals, Inc. Put Options Transaction History
Rock Springs Capital Management LP
- $1.67 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CRVS
# of Institutions
103Shares Held
37.5MCall Options Held
868KPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$24.6 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$14.4 Million0.21% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$11.6 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$9.87 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$9.49 Million0.14% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $165M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...